What is Eikon Therapeutics, Inc. 's operating income?

Eikon Therapeutics, Inc. (EIKN) reported operating income of -$87.34M in Q1 2026.

What does operating income mean?

Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Eikon Therapeutics, Inc. EIKN Operating Income

Operating Income at other companies

Frontier Group Holdings, Inc.ULCC

-$283M-515%

ANI PharmaceuticalsANIP

$38.89M+48.5%

Innoviva, Inc.INVA

$38.15M-7.9%

OmnicellOMCL

$16.85M+245%

Hycroft Mining Holding CorporationHYMC

-$50.07M-443%

Payoneer Global Inc.PAYO

$30.02M+2.4%

Other financials

Income statement

See full

Net income-$83.0M-21.6%

EPS (diluted)-$2.46+90.9%

Balance sheet

See full

Cash & equivalents$161.2M-21.2%

Total debt$254.8M—

Total equity$550.7M+186%

Total assets$850.8M—

Cash flow

See full

Operating cash flow-$89.8M-64.7%

CapEx$262.0K-98.8%

Free cash flow-$90.1M-17.1%

Valuation

See full

Market cap$514.86M—

Where this comes from

Reported directly by Eikon Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Eikon Therapeutics, Inc. ’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eikon Therapeutics, Inc. 's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Eikon Therapeutics, Inc. 's operating income?: Eikon Therapeutics, Inc. (EIKN) reported operating income of -$87.34M in Q1 2026.
What does operating income mean?: Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.